Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

Rhea-AI Summary

On June 11, 2020, Arcturus Therapeutics Holdings announced that CEO Joseph Payne will present at the Raymond James Human Health Innovation Conference, scheduled for June 15-18, 2020. The presentation is set for 3:00 pm Eastern Time on June 18. Arcturus, based in San Diego, focuses on developing messenger RNA therapeutics for rare diseases and vaccines. The company's innovative technologies include LUNAR® lipid-mediated delivery and STARR™ mRNA Technology. Arcturus has a diverse pipeline targeting conditions like Ornithine Transcarbamylase Deficiency and SARS-CoV-2.

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that Joseph Payne, President and Chief Executive Officer of Arcturus, will present at the Raymond James Human Health Innovation Conference, being held virtually during June 15-18, 2020.

100%; border-collapse:collapse !important;">

Raymond James Human Health Innovation Virtual Conference
12%; width:12%; min-width:12%;">Date/Time:	88%; width:88%; min-width:88%;">3:00 pm Eastern Time, Thursday, June 18
Location:	Virtual Track

About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (187 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, Catalent Inc., and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com

Contact
Arcturus Therapeutics
Neda Safarzadeh
(858) 900-2682
IR@ArcturusRx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008 
ctanzi@kendallir.com

FAQ

What is the date of Arcturus Therapeutics' presentation at the Raymond James Conference?

Joseph Payne, CEO of Arcturus Therapeutics, will present on June 18, 2020, at 3:00 pm Eastern Time.

Where is the Raymond James Human Health Innovation Conference being held?

The conference is being held virtually from June 15 to June 18, 2020.

What are the key technologies used by Arcturus Therapeutics?

Arcturus utilizes LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, among others.

What diseases is Arcturus Therapeutics targeting with its RNA therapeutics?

Arcturus is developing treatments for Ornithine Transcarbamylase Deficiency, Cystic Fibrosis, Hepatitis B, and others.

What is the ticker symbol for Arcturus Therapeutics?

The ticker symbol for Arcturus Therapeutics is ARCT.